London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Without a doubt a great addition to the team......Be interesting to see Immunocore IPO and market value attached to them ...another company I consider much less attractive than scancell but managed to raise £££'s from inestors and pharma
In that field for sure, this article from Fierce Biotech last January..................
Samantha Paston has ended her long association with Immunocore to take up the head of research position at Scancell. Paston’s appointment is part of a broader effort by Scancell to add experience as it steps up its immunotherapy development activities.
Scancell is developing anticancer candidates based on two immunotherapy platforms, ImmunoBody and Moditope. The pipeline of ImmunoBody vaccines, led by clinical-phase NY-ESO-1 asset SCIB1, has advanced furthest, but the other platform has attracted attention and a T-cell receptor (TCR) deal with BioNTech.
With Scancell gearing up for trials and stepping up its TCR activities, the British biotech has added Paston to its team. Paston joined Avidex, the company that became Immunocore via an acquisition and spinout, straight after earning her doctorate in 2006 and stayed on throughout the early changes and more recent upheavals.
WEBINAR CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform. REGISTER TODAY The upshot is that Paston has worked at Immunocore since it was founded in 2008. Having started out as a senior research scientist, Paston went on to lead the T cell cloning and cell biology groups during her 11 years at the TCR specialist. Paston will now apply this experience to the emerging range of R&D tasks facing Scancell.
"Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics,”
Lindy Durrant, Scancell’s founder and chief scientific officer, said in a statement. Paston will report directly to Durrant.
Scancell revealed news of Paston’s appointment alongside details of its new head of manufacturing. Adrian Parry, formerly head of small molecule CMC at Mereo BioPharma, has taken up the post, giving Scancell an employee with experience managing outsourced GMP production of clinical trial materials at a time when its manufacturing needs are growing.
Exactly that work? Well no, as I added...................Absolutely Rats, surprises me that a key member of Immunacores Research can leave the company and set up elsewhere with a Platform that was being developed with them. I thought there was something called Patents that would make that very unstraightforward.
Absolutely Rats, surprises me that a key member of Immunacores Research can leave the company and set up elsewhere with a Platform that was being developed with them. I thought there was something called Patents that would make that very unstraightforward. We should remember to that Immunacores financial position was not in its best state when she left.
We read so much about the change of key personnel, CEOs etc in the Big Pharmas every year, good to know we have enticed someone of Samanthas potential to us. Some ask do big Pharma know who we are, well it seems Lindy knows who in big Pharma to headhunt for our benefit, and it could well be a relationship between the two that perhaps led Samantha to us.
Lindy is not short of plaudits amongst us LTHs, but she is up there with every new treatment and who is leading the Research on their behalf. I cannot imagine a few years back Scancell being in a position to attract such senior staff as now, and it seems big progress is being made in the Manufacturing side with Adrian Parry at the helm too. Seeing the tangible results from our last two big appointments is a huge sign of what is to come, and at times like this comforting to know what is and might be happening behind the scenes.
There a few commercial deals that seem realistic at this time, over and above SCIB1/2 and Moditope, which could very well fund us throuh full trials and expenditure without the need for going to the market. Already we are funded to early 2021, a luxury we haven"t had for some considerable time, and when I talk of a good stratagy I mean with good fortune our funding could be secured for much longer, and start including other platforms in clinical development.
It is shame we are in a period where patience is really needed again, volumes are so low almost negidgable, but it is good to reming ourselves what we are being patient for, in these times. It is pretty pointless guessing when news will come, it can come at any time, but is essential to remind ourselves what we are being patient for. I have been doing that to a degree this weekend, wanted to ensure I kept away from speculating on speculation, we all know timelines set up at the AGM and we can just hope those will be on target. There is much going on at Scancell quite apart from just trials, which can easily get forgotten whilst the share has retreated 50% from the highs we saw after Vulpes appointment. I don"t believe it will take too much to see a return to those levels. Just MO.
"""About Scancell Holdings PLC Scancell Holdings PLC develops vaccines. The Company uses a human monoclonal antibody to target cells that stimulate immune system response. Scancell's vaccine can be customized against a specific disease."""
Following on from that article about Avidamab, many of us wondered why she had left Immunacore to join Scancell......................
"""Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab enhanced cell killing platform has broad partnering potential," said chief executive, Dr Cliff Holloway."""
Well it is a very short period of time since she left Immunacore to join Scancell, and we can see pretty clearly what she was working on there. Perhaps it was simply that Immunacore weren"t driving forward on this project, and it seems Lindy pulled off quite a coup getting her onboard here. Either way it seems it was a tremendous addition to our crew, and lets hope in another short period of time we can announce a commercial deal on this platform. I wonder what else Samanthe brought with her??
Here"s to a more interesting week here........... night guys
Scancell Scancell’s breakthrough is called AvidiMab, which works with monoclonal antibodies that already form the basis of some very effective targeted cancer treatments.
The mAbs being developed by the AIM-listed drug developer are different, however, to the run of the mill antibody.
That’s because they target tumour-associated glycans that are associated with malignancies. The ability to hone in on these so-called TaGs is enhanced with the use of AvidiMab.
Scancell has produced a pipeline of these next-generation antibodies for use in the collaboration process.
“Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab enhanced cell killing platform has broad partnering potential," said chief executive, Dr Cliff Holloway."""